| ORKA |
ORUKA THERAPEUTICS, INC. |
Common Stock, par value $0.001 per share |
9.9% |
$94,415,901 |
+$14,638,312 |
4,909,619 |
+18% |
Venrock Healthcare Capital Partners III, L.P. |
30 Sep 2025 |
| CYBN |
Cybin Inc. |
Common Shares, no par value |
9.9% |
$30,106,217 |
|
5,111,412 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Oct 2025 |
| ENGN |
enGene Holdings Inc. |
Common Shares |
9.9% |
$20,185,656 |
|
5,046,414 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |
| ZURA |
ZURA BIO LIMITED |
Class A Ordinary Shares, par value $0.0001 per share |
9.9% |
$12,897,307 |
-$1,376,174 |
6,353,353 |
-9.6% |
Venrock Healthcare Capital Partners III, L.P. |
30 Jun 2025 |
| SRZN |
Surrozen, Inc. |
Common Stock, $0.0001 par value per share |
9.9% |
$10,173,886 |
|
872,546 |
|
Venrock Healthcare Capital Partners III, L.P. |
26 Mar 2025 |
| TENX |
Tenax Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
9.9% |
$3,317,820 |
|
552,970 |
|
Venrock Healthcare Capital Partners III, L.P. |
30 Sep 2025 |
|
Vor Biopharma Inc. |
Common Stock, $0.0001 par value per share |
9.9% |
|
|
760,699 |
|
Venrock Healthcare Capital Partners III, L.P. |
18 Sep 2025 |
|
JADE BIOSCIENCES, INC. |
Common Stock, $0.0001 par value |
9.9% |
|
|
3,220,369 |
|
Venrock Healthcare Capital Partners III, L.P. |
28 Apr 2025 |
|
Crescent Biopharma, Inc. |
Ordinary Shares, $0.001 par value per share |
9.9% |
|
|
1,391,196 |
|
Venrock Healthcare Capital Partners III, L.P. |
13 Jun 2025 |
| CTMX |
CytomX Therapeutics, Inc. |
Common Stock, $0.00001 par value per share |
9.4% |
$49,641,185 |
+$8,195,110 |
15,561,500 |
+20% |
Venrock Healthcare Capital Partners III, L.P. |
30 Sep 2025 |
| ORIC |
ORIC Pharmaceuticals, Inc. |
Common Stock, par value $0.0001 per share |
7.7% |
$35,029,459 |
+$18,130,241 |
6,596,885 |
+107% |
Venrock Healthcare Capital Partners III, L.P. |
08 Apr 2025 |
| OCUL |
Ocular Therapeutix Inc |
Common Stock, $0.0001 par value per share |
7.3% |
$150,957,880 |
|
12,913,420 |
|
Venrock Healthcare Capital Partners III, L.P. |
30 Sep 2025 |
| SVRA |
Savara Inc. |
Common Stock, par value $0.001 per share |
7.3% |
$45,271,324 |
+$13,064,544 |
12,681,043 |
+41% |
Venrock Healthcare Capital Partners III, L.P. |
30 Sep 2025 |
| ELVN |
ENLIVEN THERAPEUTICS, INC. |
Common Stock, $0.001 par value per share |
5.4% |
$66,042,996 |
|
3,226,331 |
|
Venrock Healthcare Capital Partners III, L.P. |
30 Sep 2025 |
| PRAX |
Praxis Precision Medicines, Inc. |
Common Stock, par value $0.0001 per share |
4.9% |
$29,071,814 |
-$4,971,910 |
1,016,497 |
-15% |
Venrock Healthcare Capital Partners III, L.P. |
31 Mar 2025 |
| IPSC |
Century Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
4.7% |
$1,899,449 |
|
3,957,186 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |
| SYRE |
Spyre Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
4.6% |
$32,816,175 |
|
2,685,448 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |
| VRDN |
Viridian Therapeutics, Inc. |
Common Stock, $0.01 par value per share |
4.5% |
$42,152,893 |
|
3,575,309 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |
| ATXS |
Astria Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
4.4% |
$10,025,980 |
|
2,457,348 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |
| APLT |
Applied Therapeutics, Inc. |
Common Stock $0.0001 par value per share |
4.1% |
$1,781,667 |
-$1,996,029 |
5,567,709 |
-53% |
Venrock Healthcare Capital Partners III, L.P. |
31 Mar 2025 |
| PHVS |
Pharvaris N.V. |
Ordinary shares, par value EURO0.12 per share |
3.8% |
$46,767,641 |
|
2,047,620 |
|
Venrock Healthcare Capital Partners III, L.P. |
30 Jun 2025 |
| CDTX |
CIDARA THERAPEUTICS, INC. |
Common Stock, par value $0.0001 per share |
3.2% |
$42,793,332 |
-$30,795,440 |
639,088 |
-42% |
Venrock Healthcare Capital Partners III, L.P. |
30 Jun 2025 |
| DNTH |
Dianthus Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
3.1% |
$24,810,000 |
|
1,000,000 |
|
Venrock Healthcare Capital Partners III, L.P. |
30 Jun 2025 |
| AQST |
Aquestive Therapeutics, Inc. |
Common stock, $0.001 par value per share |
2.9% |
$6,232,593 |
|
2,629,786 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |
| MRSN |
MERSANA THERAPEUTICS, INC. |
Common Stock, $0.0001 par value per share |
2.9% |
$1,072,298 |
-$2,005,040 |
3,574,325 |
-65% |
Venrock Healthcare Capital Partners III, L.P. |
31 Mar 2025 |
| FDMT |
4D MOLECULAR THERAPEUTICS, INC. |
Common Stock, par value $0.0001 per share |
1.5% |
$1,795,640 |
-$6,028,143 |
677,600 |
-77% |
Venrock Healthcare Capital Partners III, L.P. |
31 Mar 2025 |
| ABVX |
Abivax SA |
Ordinary Shares, nominal value 0.01 euro per share |
0.8% |
$48,964,292 |
|
576,729 |
|
Venrock Healthcare Capital Partners III, L.P. |
30 Sep 2025 |
| ADVM |
ADVERUM BIOTECHNOLOGIES, INC. |
Common Stock, $0.0001 par value |
0% |
$0 |
|
0 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |